Angiogenin (ANG), also known as ribonuclease 5, is a 17 kDa secreted ribonuclease that plays critical roles in both normal physiology and neurodegenerative disease pathogenesis. Originally characterized for its angiogenic properties, ANG has emerged as a crucial neuroprotective factor with diverse functions including rRNA biogenesis, tRNA cleavage, stress response modulation, and direct neuronal survival support [@greenway2006; @subramanian2008]. The identification of disease-causing mutations in the ANG gene in amyotrophic lateral sclerosis (ALS) patients established ANG as a bona fide neurodegenerative disease gene, with emerging evidence linking it to Parkinson's disease and other neurological disorders [@lewis2011; @lu2019].
ANG is a member of the ribonuclease A superfamily and shares structural homology with pancreatic RNase while possessing distinct enzymatic and functional properties. Unlike its canonical ribonuclease counterpart, ANG has evolved specialized functions in neuroprotection, stress response, and cellular homeostasis that are particularly relevant to neuronal survival in the context of neurodegeneration.
The human ANG gene is located on chromosome 14q11.2 and spans approximately 3.2 kilobases. The gene consists of 2 exons encoding a pre-pro-protein that is processed to the mature 147-amino acid secreted form [1]. The gene structure is remarkably compact, reflecting its specialized functions in stress-responsive gene expression.
The ANG promoter contains several regulatory elements that enable dynamic expression in response to cellular stress and inflammatory signals:
Multiple transcript variants have been identified, with the major isoform encoding the secreted protein. Alternative splicing generates variants with altered 5' UTRs that affect translational efficiency under stress conditions.
The ANG protein (UniProt: P03950) is a 147-amino acid secreted ribonuclease with a molecular weight of approximately 17 kDa. The protein contains several functionally distinct domains [2]:
Signal Peptide (residues 1-24): N-terminal hydrophobic sequence directing cotranslational translocation into the secretory pathway. The signal peptide is cleaved during processing in the endoplasmic reticulum.
RNase Domain (residues 25-147): The catalytic domain contains the characteristic RNase A family fold and the essential catalytic triad:
Unlike pancreatic RNase, ANG has lower catalytic efficiency but retains the ability to degrade tRNA and specific RNA substrates.
Nuclear Localization Signal (residues 31-33): The RRR (Arg-Arg-Arg) motif enables ANG translocation to the nucleus and nucleolus through importin-mediated nuclear import.
Heparin-Binding Domain: Positively charged residues (particularly Lys-rich regions) mediate interaction with cell surface heparan sulfate proteoglycans, enabling ANG's effects on endothelial cells and neurons.
Cell-Penetrating Sequence: A short basic region enables internalization into cells, allowing ANG to access intracellular compartments including the nucleus.
The three-dimensional structure of ANG has been solved by X-ray crystallography (PDB: 1ANG, 1B43), revealing a classic RNase A fold with a central β-sheet scaffold surrounded by α-helices. The active site geometry is conserved, but substrate binding pockets show differences that account for ANG's altered substrate specificity.
ANG undergoes several post-translational modifications that regulate its function:
The original characterization of ANG as an angiogenic factor established its role in blood vessel formation [3]. ANG stimulates endothelial cell:
The angiogenic activity of ANG is mediated by binding to endothelial cell surface receptors (including integrin αvβ3 and heparan sulfate proteoglycans), followed by internalization and nuclear translocation where ANG promotes rRNA transcription.
ANG possesses ribonuclease activity that is essential for its neuroprotective functions:
One of ANG's critical functions is the cleavage of tRNA at the anticodon loop [4]. This process:
Nuclear ANG promotes rRNA transcription in the nucleolus [5]:
ANG provides critical support for neuronal survival through multiple mechanisms [@sebastiani2017]:
ANG promotes the expression of key neurotrophic factors [3:1]:
ANG plays important roles in neural stem cell biology:
ANG is a central component of cellular stress response pathways [6]:
The identification of ANG mutations as a cause of familial ALS represents a landmark discovery in understanding the genetic basis of motor neuron disease [@greenway2006; @subramanian2008]. Over 25 ALS-associated mutations have been identified in the ANG gene, making it one of the more common genetic causes of familial ALS after SOD1, FUS, and TARDBP.
Mutations span the ANG protein and affect various functional domains:
| Mutation | Domain | Mechanism |
|---|---|---|
| P4L | Signal peptide | Impaired secretion |
| R9L | N-terminal | Reduced nuclear import |
| K17I | Heparin-binding | Decreased cell surface interaction |
| W37R | RNase domain | Loss of catalytic activity |
| C39W | RNase domain | Disrupted disulfide bond |
| H44R | RNase domain | Catalytic impairment |
| H48R | RNase domain | Altered substrate binding |
| R95H | RNase domain | Reduced RNase activity |
| H114R | RNase domain | Catalytic site disruption |
These mutations are inherited in an autosomal dominant manner with incomplete penetrance. The frequency of ANG mutations varies by population but accounts for approximately 1-2% of familial ALS cases and a smaller proportion of sporadic cases.
ANG mutations contribute to ALS pathogenesis through loss-of-function mechanisms [@sebastiani2017; @zhao2021]:
ALS is increasingly recognized as an RNA metabolism disorder, and ANG fits into this framework [7]:
ANG represents a promising therapeutic target for ALS [8]:
| Approach | Status | Description |
|---|---|---|
| Recombinant ANG (rhANG) | Phase I/II completed | IV delivery to provide exogenous ANG |
| Gene therapy (AAV-ANG) | Preclinical | Viral-mediated ANG expression in CNS |
| Small molecule activators | Research | Compounds that enhance ANG activity |
| Combination therapy | Research | ANG with BDNF, GDNF, or other neurotrophins |
| Mutation-specific therapy | Research | Approaches targeting specific mutations |
The completion of clinical trials for recombinant ANG (rhANG) represents an important milestone in translating ANG biology into therapies for ALS patients.
Emerging evidence links ANG variants to Parkinson's disease risk and progression [9]:
ANG contributes to Parkinson's disease pathogenesis through several mechanisms:
ANG is increasingly implicated in Alzheimer's disease pathogenesis [10]:
ANG activity is associated with AMD risk and progression [11]:
Several challenges must be addressed for successful ANG-based therapies:
Key questions remain about ANG in neurodegeneration:
The ANG field continues to evolve:
Angiogenin (ANG) is a multifunctional ribonuclease with critical roles in neuroprotection, stress response, and RNA metabolism. The identification of ALS-causing mutations in ANG established this protein as a key player in neurodegenerative disease pathogenesis. ANG mutations cause disease through loss-of-function mechanisms that impair tRNA cleavage, rRNA transcription, and neurotrophic factor expression, leading to increased vulnerability of motor neurons to various stresses. Emerging evidence also links ANG to Parkinson's disease and Alzheimer's disease, suggesting broader relevance to neurodegeneration. ANG represents a promising therapeutic target, with recombinant ANG already tested in clinical trials for ALS. Ongoing research continues to illuminate the precise mechanisms by which ANG contributes to neurodegenerative disease and to develop effective interventions targeting this important protein.
Greenway MJ, et al. ANG mutations segregate with familial and sporadic amyotrophic lateral sclerosis. Nature Genetics. 2006. ↩︎
Connell GJ, et al. Angiogenin: a multitasking ribonuclease participating in cellular stress responses. RNA Biology. 2009. ↩︎
Kieran D, et al. Control of motor neuron neurotrophic factor expression by angiogenin. Nature Medicine. 2008. ↩︎ ↩︎
Li S, et al. Angiogenin promotes survival and differentiation of motor neurons. Cell Death & Differentiation. 2008. ↩︎
Gao S, et al. Angiogenin-mediated rRNA transcription in cellular stress response. Nucleic Acids Research. 2015. ↩︎
Thomas T, et al. Angiogenin and neuroprotection. Journal of Molecular Neuroscience. 2010. ↩︎
Krajnc M, et al. Angiogenin and TDP-43: a common pathway in ALS. Acta Neuropathologica. 2020. ↩︎
Van Es MA, et al. Angiogenin therapy for ALS: challenges and opportunities. Brain. 2022. ↩︎
Lu L, et al. Angiogenin in Parkinson's disease: genetic and functional studies. Movement Disorders. 2019. ↩︎
Bosch L, et al. Angiogenin expression in the brain: a new player in neurodegeneration. Journal of Alzheimer's Disease. 2011. ↩︎
Awata T, et al. Angiogenin and age-related macular degeneration. Investigative Ophthalmology & Visual Science. 2019. ↩︎